HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 2,500
- 试验地点
- 79
- 主要终点
- The primary objective of this study is:
研究概览
简要总结
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
详细描述
This is a longitudinal open-ended observational study. Participants will attend two annual study visits, an Annual Screening Visit followed by an Annual Sampling Visit, and may also attend an optional visit during the first year of enrollment, an Optional Repeat Sampling Visit.
During the Annual Screening Visit, medical history, and clinical and phenotypic data will be obtained. Participants who meet the eligibility requirements of the study and are willing to continue in the study, will return for an Annual Sampling Visit. During that visit, biosamples will be collected following a fast of at least 6 hours, or overnight: blood will be obtained via venipuncture and CSF will be obtained via lumbar puncture. Some participants may be invited to return for an Optional Repeat Sampling Visit approximately 4-8 weeks after the Annual Sampling Visit during their first year of enrolment.
The annual visits are at regular intervals after the first Annual Screening Visit (i.e. at 1, 2, 3 years and so on) ± 2 months. Participants will be encouraged to complete all annual visits; however, they are under no obligation to take part and will be able to skip annual visit without being discontinued from the study. Participants who do not come for an Annual Sampling Visit for three consecutive years will be discontinued from the study, but they may enrol again at a later date, if they so consent. Participants who have already completed HDClarity Sampling Visits under earlier versions of this protocol may also participate in the longitudinal study if they meet the eligibility criteria.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 11 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD)
- •Enroll HD participant
- •Capable of consenting or have a legal representative (parent/guardian for juveniles)
- •Capable of complying with study procedures
- •All participants other than family and community controls must have had a genetic test for HD
排除标准
- •Drug trial within 30 days of any sampling visit
- •Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days)
- •Antiplatelet or anticoagulant therapy within 14 days
- •Significant comorbidity
- •Needle phobia, headache, spinal surgery / deformity
- •Clotting or bruising disorder
- •Screening blood test abnormalities >10% outside normal range
- •Drug / alcohol abuse
- •Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential
- •Predictable non compliance or unwillingness
- •Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days
研究组 & 干预措施
Advanced Manifest HD
Participants eligible are persons who meet the following criteria:
- Are 21-75 years of age, inclusive, at the time of consent; and
- Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
- Have CAG expansion ≥ 40; and
- Have Stage IV HD, defined as UHDRS TFC scores between 0 and 2, inclusive
Incomplete Penetrance HD
Participants eligible are persons who meet the following criteria:
- Are 18-75 years of age, inclusive, at the time of consent; and
- Have CAG expansion of 36-39
Juvenile Manifest HD
Participants eligible are persons who meet the following criteria:
- Are ≥11 years of age at the time of consent; and
- Have clinical diagnostic features of juvenile HD, defined as UHDRS Diagnostic Confidence Score = 4 aged ≤20 years; and
- Have CAG expansion ≥ 40
Early Pre-manifest HD
Participants eligible are persons who meet the following criteria:
- Are 18-75 years of age, inclusive, at the time of consent; and
- Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
- Have CAG expansion ≥ 40; and
- Have burden of pathology score, computed as (CAG - 35.5) × age, < 250
Late Pre-manifest HD
Participants eligible are persons who meet the following criteria:
- Are 18-75 years of age, inclusive, at the time of consent; and
- Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
- Have CAG expansion ≥ 40; and
- Have burden of pathology score, computed as (CAG - 35.5) x age, ≥ 250
Early Manifest HD
Participants eligible are persons who meet the following criteria:
- Are 21-75 years of age, inclusive, at the time of consent; and
- Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
- Have CAG expansion ≥ 40; and
- Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 13 inclusive
Moderate Manifest HD
Participants eligible are persons who meet the following criteria:
- Are 21-75 years of age, inclusive, at the time of consent; and
- Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
- Have CAG expansion ≥ 40; and
- Have Stage III HD, defined as UHDRS TFC scores between 3 and 6, inclusive
Healthy Control
Participants eligible are persons who meet the following criteria:
- Are 18-75 years of age, inclusive, at the time of consent; and
- Have no known family history of HD; or
- Have known family history of HD but have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG < 36).
结局指标
主要结局
The primary objective of this study is:
时间窗: years N/A
To generate a high quality CSF sample collection for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD.
次要结局
- The secondary objectives of this study are:(years N/A)
研究者
Edward Wild
Dr
University College, London